1. Home
  2. BBY vs INCY Comparison

BBY vs INCY Comparison

Compare BBY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Best Buy Co. Inc.

BBY

Best Buy Co. Inc.

HOLD

Current Price

$72.59

Market Cap

15.6B

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$96.64

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBY
INCY
Founded
1966
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6B
17.0B
IPO Year
N/A
1993

Fundamental Metrics

Financial Performance
Metric
BBY
INCY
Price
$72.59
$96.64
Analyst Decision
Buy
Buy
Analyst Count
19
21
Target Price
$84.24
$94.94
AVG Volume (30 Days)
4.0M
2.1M
Earning Date
11-25-2025
10-28-2025
Dividend Yield
5.24%
N/A
EPS Growth
N/A
3878.02
EPS
3.02
5.90
Revenue
$41,825,000,000.00
$4,813,105,000.00
Revenue This Year
$1.77
$19.59
Revenue Next Year
$1.32
$10.88
P/E Ratio
$24.01
$16.38
Revenue Growth
N/A
18.09
52 Week Low
$54.99
$53.56
52 Week High
$91.68
$109.28

Technical Indicators

Market Signals
Indicator
BBY
INCY
Relative Strength Index (RSI) 37.17 40.50
Support Level $74.24 $100.55
Resistance Level $83.67 $103.68
Average True Range (ATR) 2.57 3.22
MACD -0.41 -1.26
Stochastic Oscillator 1.08 17.14

Price Performance

Historical Comparison
BBY
INCY

About BBY Best Buy Co. Inc.

With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: